CIK 0001488039 · Non-accelerated filer<br>Smaller reporting company
ATOSSA THERAPEUTICS, INC.
Sign in to watch- Ticker
- ATOS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 264753208
- Phone
- 206.588.0256
- Business address
- 1448 NW MARKET STREET, SUITE 500, SEATTLE, WA, 98107
- Former names
- ATOSSA GENETICS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2019-05-17 | Steinhart Richard I Director | Grant or award · Stock Option (right to buy) | +45,000 | 45,000 | ||
| 2019-05-17 | Galli Stephen J Director | Grant or award · Stock Option (right to buy) | +45,000 | 45,000 | ||
| 2019-05-17 | Remmel H. Lawrence Director | Grant or award · Stock Option (right to buy) | +45,000 | 45,000 | ||
| 2019-05-17 | Chen Shu-Chih Director | Grant or award · Stock Option (right to buy) | +45,000 | 45,000 | ||
| 2019-01-13 | QUAY STEVEN C President & CEO | Returned to the company · Stock Option (Right to Buy) | −2,300,000 | 0 | ||
| 2019-01-13 | QUAY STEVEN C President & CEO | Grant or award · Stock Option (Right to Buy) | +2,300,000 | 2,300,000 | ||
| 2019-01-13 | Guse Kyle CFO, Gen Counsel and Secretary | Returned to the company · Stock Option (Right to Buy) | −700,000 | 0 | ||
| 2019-01-13 | Guse Kyle CFO, Gen Counsel and Secretary | Grant or award · Stock Option (Right to Buy) | +800,000 | 800,000 | ||
| 2018-06-27 | Guse Kyle CFO, Gen Counsel and Secretary | Grant or award · Stock Option (right to buy) | +700,000 | 700,000 | ||
| 2018-06-27 | Remmel H. Lawrence Director | Grant or award · Stock Option (right to buy) | +45,000 | 45,000 | ||
| 2018-06-27 | Steinhart Richard I Director | Grant or award · Stock Option (right to buy) | +45,000 | 45,000 | ||
| 2018-06-27 | QUAY STEVEN C President & CEO | Grant or award · Stock Option (right to buy) | +2,300,000 | 2,300,000 | ||
| 2018-06-27 | Chen Shu-Chih Director | Grant or award · Stock Option (right to buy) | +45,000 | 45,000 | ||
| 2018-06-27 | Galli Stephen J Director | Grant or award · Stock Option (right to buy) | +45,000 | 45,000 | ||
| 2018-06-27 | WEAVER GREGORY L Director | Grant or award · Stock Option (right to buy) | +45,000 | 45,000 | ||
| 2018-05-30 | Chen Shu-Chih Director | Purchase · Series B Convertible Preferred Stock | +8 | $1,000.00 | $8K | 8 |
| 2018-05-30 | Chen Shu-Chih Director | Purchase · Warrants | +2,272 | $1,000.00 | $2.3M | 2,272 |
| 2018-05-30 | QUAY STEVEN C President & CEO | Purchase · Series B Convertible Preferred Stock | +8 | $1,000.00 | $8K | 8 |
| 2018-05-30 | QUAY STEVEN C President & CEO | Purchase · Warrants | +2,272 | $1,000.00 | $2.3M | 2,272 |
| 2018-05-30 | Guse Kyle CFO, Gen Counsel and Secretary | Purchase · Series B Convertible Preferred Stock | +8 | $1,000.00 | $8K | 8 |
Page 5 of 9 · 168 trades